Search results for "Neoplasms."

showing 10 items of 7882 documents

Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma.

2002

Heat shock proteins (HSP) are families of highly conserved proteins which are induced in cells and tissues upon exposure to extreme conditions causing acute or chronic stress. They exhibit distinct functions and have been implicated in the pathogenesis of a number of diseases, including cancer. A causal relationship between HSP expression and immunogenicity has been demonstrated in murine and human tumors and is also associated with the immune response. In order to investigate the correlation of HSP expression and their immunogenic potential in renal cell carcinoma (RCC), we here analyzed (i) the protein expression profile of various members of the HSP family in untreated and interferon (IF…

medicine.medical_treatmentBiologyurologic and male genital diseasesKidneyBiochemistryPathogenesisInterferon-gammaMiceImmune systemInterferonHeat shock proteinmedicineTumor Cells CulturedAnimalsHumansInterferon gammaElectrophoresis Gel Two-DimensionalMolecular BiologyCarcinoma Renal CellHeat-Shock ProteinsKidneyImmunogenicityEpithelial CellsKidney NeoplasmsNeoplasm ProteinsCytokinemedicine.anatomical_structureSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologyCancer researchmedicine.drugProteomics
researchProduct

Synthesis of biotin-labelled dexamethasone derivatives. Novel hormone-affinity probes.

1983

A new, general methodology for 'sandwich' affinity chromatography of steroid hormone receptors is proposed, the part purification of the human spleen tumor glucocorticoid receptor is quoted as an illustration. 9-Fluoro-16 alpha-methyl-11 beta, 17-dihydroxy-1,4-androstadiene-3-one-17 beta-carboxylic acid was coupled to biotin using pentamethylenediamine (BioDex 1) as a spacer. The bifunctional derivative binds to glucocorticoid receptors and avidin-Sepharose and efficiently protects the glucocorticoid receptor against inactivation when previously added during homogenisation. We have standardized the capacity and optimum conditions for elution of receptor-BioDex-1 complexes which are bound to…

medicine.medical_treatmentBiotinBiochemistryBinding CompetitiveChromatography AffinityDexamethasoneSteroidchemistry.chemical_compoundGlucocorticoid receptorCytosolReceptors GlucocorticoidAffinity chromatographyBiotinCadaverinemedicineHumansBinding siteReceptorPolyacrylamide gel electrophoresisChromatographyBinding SitesChemistrySplenic NeoplasmsAffinity LabelsSteroid hormoneBiochemistryElectrophoresis Polyacrylamide GelEuropean journal of biochemistry
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Optimal application of compressive palatal stents following mesiodens removal in pediatric patients:a Randomized Controlled Trial

2021

Background There is no scientific evidence supporting the choice of a palatal stent in patients who underwent removal of an impacted supernumerary tooth. We aimed to investigate the effects of palatal stents in patients who underwent supernumerary tooth removal through a palatal approach and to suggest the optimal stent thickness and material. Material and Methods We recruited 144 patients who underwent extraction of a supernumerary tooth between the maxillary anterior teeth. Subjects were assigned to a control group (CG) or one of four compressive palatal stent groups (CPSGs) classified by the thickness and material of the thermoplastic acrylic stent used. Palatal gingival swelling and obj…

medicine.medical_treatmentDentistryOral hygieneGingival swellinglaw.inventionRandomized controlled triallawMedicineHumansSupernumeraryIn patientdelayed diagnosisChildGeneral DentistryAnterior teethUNESCO:CIENCIAS MÉDICASbusiness.industryPalateResearchmouth neoplasmsTooth ImpactedStentoral neoplasmagedOtorhinolaryngologyTooth SupernumeraryTooth ExtractionSurgeryStentsSwellingmedicine.symptomOral Surgerybusiness
researchProduct

The impact of head and neck radiotherapy on the dentine-enamel junction: a systematic review

2019

Background Radiotherapy is widely used in contemporary head and neck cancer treatment protocols. The ability of head and neck radiotherapy (HNRT) to cause direct radiogenic destruction to the teeth is one of the most controversial topics in the field of oral oncology. Therefore, this systematic review aimed to investigate ionising radiation as an independent factor for physical and chemical changes on the dentine-enamel junction (DEJ), a pivotal dental topography for the onset and progression of radiation-related caries (RRC) and enamel delamination. Material and Methods Systematic searches were conducted on three databases: Scopus, MEDLINE (Via PubMed) and Embase (Elsevier). Laboratory stu…

medicine.medical_treatmentDentistryReviewDental Caries03 medical and health sciences0302 clinical medicinestomatognathic systemHead and neck radiotherapyDentinHumansMedicineDental EnamelMethodological qualityGeneral DentistryOral Medicine and PathologyEnamel paintbusiness.industryHead and neck cancerCancer030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseQuality of evidenceRadiation therapystomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyHead and Neck Neoplasmsvisual_artDentinUNESCO::CIENCIAS MÉDICASvisual_art.visual_art_mediumSurgerybusinessToothMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

The Potential Use of Resveratrol for Cancer Prevention.

2019

In addition to the traditional treatments of cancer and cancer prevention, the use of natural compounds, especially those found in food, should be considered. To clarify if resveratrol has the potential for cancer prevention and the possibility of use in therapy, the following must be taken into account: data from epidemiology, clinical protocol (case and control), preclinical studies (lab animals), use of established cell lines as models of cancer cells, test tube assays (enzymes activities), and requirements of nanotechnologies in order to discover new drugs to fight cancer. From this perspective and future expected advances, more information is needed such as improved efficacy, methods o…

medicine.medical_treatmentDrug Evaluation PreclinicalPharmaceutical ScienceReviewResveratrolresveratrolBioinformaticsChemopreventionAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepreventionNeoplasmsDrug DiscoverymedicineAnimalsHumanscancerPhysical and Theoretical ChemistrySensitization030304 developmental biology0303 health sciencesmechanismsCancer preventionbusiness.industryOrganic ChemistryClinical Studies as TopicCancerDisease Managementmedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilitymedicine.anatomical_structurechemistryChemistry (miscellaneous)030220 oncology & carcinogenesisapproach strategiesCancer cellMolecular MedicineDisease Susceptibilitybusinessinnovative formulationsAdjuvantSignal TransductionMolecules (Basel, Switzerland)
researchProduct